Breast Neoplasms, mTor Protein
Conditions
Keywords
Hormonoresistance, tamoxifen, Previously received anti-aromatase treatment, mTor inhibitor
Brief summary
Tamoxifen is a classical treatment for breast metastatic cancer after 3rd generation anti-aromatase hormonotherapy in adjuvant or in metastatic line. The Tamoxifen efficacy is lowered by the hormonoresistance mechanisms due to the primary use of the anti-aromatases. The Pi3K-AKT-mTor pathway is frequently associated to the hormonoresistance mechanisms. This study is aimed to check if the inhibition of this signal transduction pathway by a synthetic mTor inhibitor (Everolimus) could improve the efficacy of the Tamoxifen.
Interventions
DRUGTamoxifen
20mg daily (1 cap) until unbearable toxicity or progression
DRUGEverolimus
10mg daily (2 caps of 5mg) until unbearable toxicity or progression
Sponsors
Novartis
ARCAGY/ GINECO GROUP
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Menopausal female patient aged \> 18 years * Histologically proven breast adenocarcinoma * ER and/or PR positive receptors and HER2 negative * previously received first or second line of hormonotherapy for metastatic disease * previously treated with anti-aromatase in adjuvant and/or in metastatic line * presence of one or several mesurable or evaluable metastatic lesion(s) * presence of at least one target lesion not previously irradiated * ECOG Performance status \< 2 * adequate biological values * patient who has clearly given her consent by signing on informed consent form prior to participation
Exclusion criteria
* patient with only local metastatic disease that can be treted by surgery * uncotrolled brain metastases, pulmonary carcinomatosal lymphangitis, hepatic metastases * Previous treatment by Tamoxifen unless in adjuvant and terminated more than a year before metastatic relapse * Patient with a tumor surexpressing HER2 that should be treated by trastuzumab * Patient that need an immediate local antalgic radiotherapy * Thrombo-embolism disease * serious concomitant pathology or uncontrolled that is susceptible to compromise the participation in the study * history of another malignancy within past 5 years that could confound diagnosis or staging of breast cancer (with the exception of in situ cacinoma of the cervix or adequately treated basel cell carcinoma of the skin) and cancers cured for at least for 5 years * patient with an history of significant cardiovascular impairment (congestive heart failure\> NYHA grade II, unstable angina or myocardial infraction within the past six months or serious cardiac arrhythmia) * patient with any medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude her from participating in this study * patient with a known allergy to one or several of the study compounds * patients who may not be regularly available due to geographical, social or family reasons * history of renal, hepatic or metabolic pathology that could preclude with metabolism or elimination of the study product * deficiencies of the upper intestinal tract, malabsorption syndrome * patient who is pregnant, breast-feeding or using inadequate contraception * Treatment with experimental drugs (mTor inhibitor or tyrosin kinase inhibitor) * Patient treated with molecules that interfer with isoenzyme CYP3A
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical benefit at 24 weeks | 42 months |
Secondary
| Measure | Time frame |
|---|---|
| Partial and complete response per RECIST | 42 months |
| Qualitative and quantitative toxicities | 24 months |
| Overall survival | 42 months |
Countries
France
Outcome results
None listed